20 August 2019 News
AstraZeneca has announced that Farxiga (dapagliflozin) met its primary endpoint in heart failure-focused Phase III DAPA-HF trial of patients with reduced ejection fraction (HFrEF).
19 August 2019 News
Researchers from Virginia Tech University (VT) have developed a variant of the compound alphaCT1, which can improve heart attack recovery if administered during, or soon after, a heart attack.
18 July 2019 Comment
Forxiga is indicated for monotherapy and combination therapy use to improve glycemic control with the additional benefits of weight loss and blood pressure reduction.
17 June 2019 Comment
Amarin’s Vascepa, AstraZeneca’s Epanova theoretical cardiovascular risk reduction class effect possibly stifled
Although Amarin’s Vascepa (icosapent ethyl) is likely to lock in US Food and Drug Administration approval and swift uptake in cardiovascular disease (CVD) risk reduction, there could be future competition...
23 April 2019 pressreleases
Creative Pharma Services attended the Hellenic Society for Pharmaceutical Management on 18 April.
27 March 2019 Comment
Abbott’s MagLev pump technology is thought to be responsible for the reduction of many severe complications of end-stage heart failure treatment.